. "Infantiln\u00ED hemangiomy (IH) \u2013 nej\u010Dast\u011Bj\u0161\u00ED benign\u00ED n\u00E1dory kojenc\u016F \u2013 postihuj\u00ED 10 a\u017E 12 % kojenc\u016F, v\u011Bt\u0161inou spont\u00E1nn\u011B involuj\u00ED, 10\u201320 % progreduj\u00EDc\u00EDch IH m\u016F\u017Ee p\u016Fsobit z\u00E1va\u017En\u00E9 funk\u010Dn\u00ED obt\u00ED\u017Ee nebo kosmetick\u00E9 vady. IH se d\u011Bl\u00ED do t\u0159\u00ED skupin: povrchov\u00E9 (superfici\u00E1ln\u00ED) 50\u201360 %, podko\u017En\u00ED (hlubok\u00E9) 15 % a sm\u00ED\u0161en\u00E9 25\u201335 %. Velikost a po\u010Det lo\u017Eisek je zna\u010Dn\u011B variabiln\u00ED. Leaut\u00E9-Labr\u00E9ze publikovala (2008) prvn\u00ED zku\u0161enost s pou\u017Eit\u00EDm betablok\u00E1toru propranololu jako \u00FA\u010Dinn\u00E9 l\u00E9\u010Dby IH. Propranolol zp\u016Fsobuje vazokonstrikci, blokuje \u00FA\u010Dinky faktor\u016F podporuj\u00EDc\u00EDch novotvorbu c\u00E9v a podporuje apopt\u00F3zu endoteli\u00E1ln\u00EDch bun\u011Bk. 103 d\u011Bt\u00ED, chlapci \u2013 20 (22 %), d\u00EDvky \u2013 83 (78 %), medi\u00E1n v\u011Bku 4,6 m\u011Bs\u00EDc\u016F. Lokalizace IH: hrudn\u00EDk 16 (15 %), j\u00E1tra samostatn\u011B 4 (4 %), j\u00E1tra + k\u016F\u017Ee mnoho\u010Detn\u011B 2 (2 %), kon\u010Detina 11 (10 %), mnoho\u010Detn\u00E9 13 (12 %), hlava, obli\u010Dej 63 (58 %). C\u00EDlov\u00E1 d\u00E1vka propranololu 2 mg/kg/den, d\u00E9lka l\u00E9\u010Dby: med\u00ED\u00E1n 6,4 m\u011Bs\u00EDc\u016F (3 m\u011Bs.; 2,5 roku); hemangiomy jater l\u00E9\u010Deny med. 9,7 m\u011Bs\u00EDc\u016F. U 9 (9 %) IH po vysazen\u00ED propranololu bylo nutn\u00E9 l\u00E9\u010Dbu znovu nasadit. Superfici\u00E1ln\u00ED hemangiomy reagovaly nejl\u00E9pe, zmizely bez patrn\u00E9ho rezidua. Hlubok\u00E9 hemangiomy reagovaly pomaleji. Sm\u00ED\u0161en\u00E9 hemangiomy zanechaly v 5 p\u0159\u00EDpadech reziduum, kter\u00E9 bylo nutn\u00E9 odstranit chirurgicky, ve 3 p\u0159\u00EDpadech se rezidua o\u0161et\u0159ovala laserem. Vedlej\u0161\u00ED projevy: 3x n\u00EDzk\u00E1 tepov\u00E1 frekvence, 2x hypoglykemie (nejni\u017E\u0161\u00ED 2,8 mmol/l), 1x ko\u017En\u00ED alergick\u00E1 reakce na sirup, kter\u00E1 ustoupila rychle po vysazen\u00ED. Z projev\u016F uv\u00E1d\u011Bn\u00FDch rodi\u010Di \u2013 studen\u011Bj\u0161\u00ED akra." . . "RIV/00216208:11120/14:43909065" . "CZ - \u010Cesk\u00E1 republika" . "0069-2328" . "Betablok\u00E1tory v l\u00E9\u010Db\u011B hemangiom\u016F d\u011Btsk\u00E9ho v\u011Bku" . "5" . "Sukop, Andrej" . "I" . "9"^^ . "11120" . "Betablok\u00E1tory v l\u00E9\u010Db\u011B hemangiom\u016F d\u011Btsk\u00E9ho v\u011Bku"@cs . "Infantile hemangiomas (IH) \u2013 the most common benign tumors in infants affects 10% to 12% of infants, usually spontaneously involuting, 10\u201320% progressing IH can cause serious functional problems or cosmetic defect. IH is divided into three groups: superficial 50\u201360%, subcutaneous (deep) 15%, and mixed 25\u201335%. The size and number of deposits is highly variable. Leaute-Labr\u00E9ze published (2008) first experience with the use of beta-blocker propranolol as an effective treatment for IH. Propranolol causes vasoconstriction, blocks the effects of the factors supporting the formation of new blood vessels and promotes apoptosis of endothelial cells. 103 children, boys 20 (22%) , girls 83 (78%), med. age 4.6 months. Location of IH: chest 16 (15%), liver 4 (4%) , liver + skin 2 (2%) , limbs 11 (10%), multiple localization 13 (12%), head, face 63 (58%). The target dose of propranolol 2 mg/kg/day, duration of treatment: med. 6.4 months (3 months, 2.5 years), hemangiomas of the liver treated med. 9.7 months. In 9 pts (9%) IH after discontinuation of propranolol therapy should be resumed. Superficial hemangiomas responded best, disappeared without appreciable residue. Deep hemangiomas responded slowly. Mixed hemangiomas leaving residue in 5 cases, must be removed surgically, in 3 cases the residues are treated with laser therapy. Secondary symptoms: 3 low heart rate, 2 hypoglycemia (lowest level 2.8 mmol/l), 1 skin allergic reaction to a syrup, which resolved rapidly after discontinuation. The parents observation \u2013 colder acres."@en . . "[9DFFE4F6A914]" . . . "Beta-blockers in the treatment of hemangiomas in childhood"@en . "Betablok\u00E1tory v l\u00E9\u010Db\u011B hemangiom\u016F d\u011Btsk\u00E9ho v\u011Bku"@cs . . . . "69" . "Betablok\u00E1tory v l\u00E9\u010Db\u011B hemangiom\u016F d\u011Btsk\u00E9ho v\u011Bku" . "propranolol; beta-blockers; infantile hemangioma; hemangioma"@en . "\u010Cesko-slovensk\u00E1 pediatrie" . "RIV/00216208:11120/14:43909065!RIV15-MSM-11120___" . . . "17"^^ . . . "5107" . "1"^^ . . "Infantiln\u00ED hemangiomy (IH) \u2013 nej\u010Dast\u011Bj\u0161\u00ED benign\u00ED n\u00E1dory kojenc\u016F \u2013 postihuj\u00ED 10 a\u017E 12 % kojenc\u016F, v\u011Bt\u0161inou spont\u00E1nn\u011B involuj\u00ED, 10\u201320 % progreduj\u00EDc\u00EDch IH m\u016F\u017Ee p\u016Fsobit z\u00E1va\u017En\u00E9 funk\u010Dn\u00ED obt\u00ED\u017Ee nebo kosmetick\u00E9 vady. IH se d\u011Bl\u00ED do t\u0159\u00ED skupin: povrchov\u00E9 (superfici\u00E1ln\u00ED) 50\u201360 %, podko\u017En\u00ED (hlubok\u00E9) 15 % a sm\u00ED\u0161en\u00E9 25\u201335 %. Velikost a po\u010Det lo\u017Eisek je zna\u010Dn\u011B variabiln\u00ED. Leaut\u00E9-Labr\u00E9ze publikovala (2008) prvn\u00ED zku\u0161enost s pou\u017Eit\u00EDm betablok\u00E1toru propranololu jako \u00FA\u010Dinn\u00E9 l\u00E9\u010Dby IH. Propranolol zp\u016Fsobuje vazokonstrikci, blokuje \u00FA\u010Dinky faktor\u016F podporuj\u00EDc\u00EDch novotvorbu c\u00E9v a podporuje apopt\u00F3zu endoteli\u00E1ln\u00EDch bun\u011Bk. 103 d\u011Bt\u00ED, chlapci \u2013 20 (22 %), d\u00EDvky \u2013 83 (78 %), medi\u00E1n v\u011Bku 4,6 m\u011Bs\u00EDc\u016F. Lokalizace IH: hrudn\u00EDk 16 (15 %), j\u00E1tra samostatn\u011B 4 (4 %), j\u00E1tra + k\u016F\u017Ee mnoho\u010Detn\u011B 2 (2 %), kon\u010Detina 11 (10 %), mnoho\u010Detn\u00E9 13 (12 %), hlava, obli\u010Dej 63 (58 %). C\u00EDlov\u00E1 d\u00E1vka propranololu 2 mg/kg/den, d\u00E9lka l\u00E9\u010Dby: med\u00ED\u00E1n 6,4 m\u011Bs\u00EDc\u016F (3 m\u011Bs.; 2,5 roku); hemangiomy jater l\u00E9\u010Deny med. 9,7 m\u011Bs\u00EDc\u016F. U 9 (9 %) IH po vysazen\u00ED propranololu bylo nutn\u00E9 l\u00E9\u010Dbu znovu nasadit. Superfici\u00E1ln\u00ED hemangiomy reagovaly nejl\u00E9pe, zmizely bez patrn\u00E9ho rezidua. Hlubok\u00E9 hemangiomy reagovaly pomaleji. Sm\u00ED\u0161en\u00E9 hemangiomy zanechaly v 5 p\u0159\u00EDpadech reziduum, kter\u00E9 bylo nutn\u00E9 odstranit chirurgicky, ve 3 p\u0159\u00EDpadech se rezidua o\u0161et\u0159ovala laserem. Vedlej\u0161\u00ED projevy: 3x n\u00EDzk\u00E1 tepov\u00E1 frekvence, 2x hypoglykemie (nejni\u017E\u0161\u00ED 2,8 mmol/l), 1x ko\u017En\u00ED alergick\u00E1 reakce na sirup, kter\u00E1 ustoupila rychle po vysazen\u00ED. Z projev\u016F uv\u00E1d\u011Bn\u00FDch rodi\u010Di \u2013 studen\u011Bj\u0161\u00ED akra."@cs . . "Beta-blockers in the treatment of hemangiomas in childhood"@en . .